- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioLineRx Ltd (BLRX)
The BioLineRx share price today is 2.430, view NASDAQ BLRX stock exchange data. Track the latest BioLineRx share price with real-time updates on BLRX stock performance including market cap, day range, 52-week range and dividend yield. Access BLRX charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.430
2.520
52 wk Range
2.150
4.560
BLRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.4302.520
52 wk Range
2.1504.560
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BLRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
22.000
Upside
+805.35%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 22.000
(+805.35% Upside)
BioLineRx Ltd Earnings Call Summary for Q2/2026
- Q2 2026 revenue flat at $0.3M from APHEXDA royalties; net loss widened to $4.3M from $3.9M year-over-year amid higher R&D spending.
- Lead drug GLIX1 advanced in phase I/IIa trials across three centers with favorable safety data; preclinical results show synergy with PARP inhibitors.
- Company ended quarter with $13.1M cash, raised additional $3.75M; combined funds expected to support operations into first half of 2027.
- Key milestones include GLIX1 third cohort dosing in Sept 2026, data presentations at EANO/SNO/ESMO, and phase I results expected H1 2027.
- Motixafortide pancreatic cancer program awaits interim futility analysis in late 2026 to determine next steps amid evolving competitive landscape.
Last Updated: 31-08-2026, 07:50 pm
Read Full TranscriptEarnings
Latest Release
31-08-2026
EPS / Forecast
-- / --
Revenue / Forecast
294K / --
Compare BLRX to Peers and Sector
Metrics to compare | BLRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −1.5x | −0.4x | |
PEG Ratio | −0.04 | 0.03 | 0.00 | |
Price/Book | 0.8x | 2.2x | 2.6x | |
Price / LTM Sales | 8.0x | 8.4x | 3.0x | |
Upside (Analyst Target) | - | 128.5% | 54.5% | |
Fair Value Upside | Unlock | 8.3% | 7.8% | Unlock |
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the BioLineRx (BLRX) Share Price Today?
The BioLineRx share price today is 2.430.
What is the current BioLineRx (BLRX) share price and day range?
As of 15-09-2026, the BioLineRx share price is 2.430, with a previous close of 2.510. The share price has ranged from 2.430 to 2.520 today, while the 52-week range spans from 2.150 to 4.560.
What Is the BioLineRx Market Cap?
As of today, BioLineRx market cap is 11.200M.
What Is the BioLineRx (BLRX) Share Price Target?
The average 12-month share price target for BioLineRx is 22.000, with a high estimate of 26 and a low estimate of 18. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +805.35% Upside potential.
What Is BioLineRx's Earnings Per Share (TTM)?
The BioLineRx EPS (TTM) is -0.003.
When Is the Next BioLineRx Earnings Date?
BioLineRx will release its next earnings report on 24-11-2025.
From a Technical Analysis Perspective, Is BLRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does BioLineRx Trade On?
BioLineRx is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for BioLineRx?
The stock symbol for BioLineRx is "BLRX."
How Many Times Has BioLineRx Stock Split?
BioLineRx has split 2 times.
How Many Employees Does BioLineRx Have?
BioLineRx has 22 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.